Cumberland Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cumberland Pharmaceuticals Inc. on April 21, 2026, regarding the annual meeting of shareholders held on the same date in Nashville, Tennessee. The filing details the results of shareholder votes on director elections, auditor ratification, and executive compensation matters.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes
No material financial changes or operational updates are reported in this filing. The document serves solely to disclose the outcomes of the shareholder vote.
Guidance, Outlook, and Voting Results
Shareholders approved the following matters with high levels of support:
- Director Elections: Kenneth J. Krogulski was elected with 99.52% of votes in favor; Caroline R. Young was elected with 98.66% of votes in favor.
- Auditor Ratification: Carr, Riggs & Ingram, LLC was ratified as the independent registered public accounting firm for the year ending December 31, 2026, with 99.82% of votes in favor.
- Executive Compensation (Say-on-Pay): The advisory vote on executive compensation received 99.82% of votes in favor.
- Compensation Vote Frequency: Shareholders voted on the frequency of future advisory votes. The "Every Year" option received 1,733,309 votes, while the "Every Three Years" option received 7,844,848 votes, indicating a preference for triennial voting.
Key Facts for Investor Verification
- Verify the official appointment of Carr, Riggs & Ingram, LLC as the auditor for the 2026 fiscal year.
- Confirm the board composition following the election of Class I Directors Kenneth J. Krogulski and Caroline R. Young.
- Note the shareholder preference for a three-year frequency for future executive compensation advisory votes.
- Review subsequent filings (e.g., 10-K or 10-Q) for actual financial performance data, as this 8-K contains no financial metrics.